fda glp-1 compounding warning september 2025 weight loss drugs are back in the news FDA is short-sighted on compounding

Most patients qualify with a BMI of 30+ BMI 27+ with weight-related conditions may also qualify BMI is only a starting point, not the full picture BMI is merely an indicator and not absolutely everything

Setayesh et al., 2019

Morgan, in a June note, pegged $65, praising Hims innovative GLP-1 push and 41% subscriber growth

But if it were that simple, wouldnt we all be at our ideal weight

Committee members examined peptides for designated purposes, but many users claim benefits that go far beyond touted uses

Weve found that people generally tolerate GLP-1 for weight loss well, and the side effect profile seems to be fairly mild and predictable